ROHIT PAL

Mr. ROHIT PAL

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BKB. Kumaraswamy
B. Kumaraswamy
KHK. Hemalatha
K. Hemalatha
RPROHIT PAL
ROHIT PAL
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
KHKetan R. Hosamani
Ketan R. Hosamani
NANimmagadda Venkata Satya Sai Aishwarya
Nimmagadda Venkata Satya Sai Aishwarya

11 September 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
KHKetan R Hosamani
Ketan R Hosamani
HKHemalatha K
Hemalatha K
RPROHIT PAL
ROHIT PAL
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
KBKumaraswamy B
Kumaraswamy B
NANimmagadda Venkata Satya Sai Aishwarya
Nimmagadda Venkata Satya Sai Aishwarya

31 May 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PDPronoy Kanti Das
Pronoy Kanti Das
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
RPROHIT PAL
ROHIT PAL
LMLalmohan Maji
Lalmohan Maji
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
MVM.P. Viji
M.P. Viji

6 September 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AIAayishamma I
Aayishamma I
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
RPROHIT PAL
ROHIT PAL
AGAbhishek Ghara
Abhishek Ghara
NANimmagadda Venkata Satya Sai Aishwarya
Nimmagadda Venkata Satya Sai Aishwarya
HEHaripriya E
Haripriya E

9 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
RPROHIT PAL
ROHIT PAL
ESEkta Singh
Ekta Singh
AGAbhishek Ghara
Abhishek Ghara
GAGanesh Andhale
Ganesh Andhale
Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor receptor 2 (HER2) gets activated when its endogenous ligand(s) bind to its ATP binding site of target receptors. In breast cancer (BC), EGFR and HER2 are two proteins are overexpressed which leads to overexpression of cells proliferation and decreases cell death/apoptosis. Pyrimidine is one of the most widely studied heterocyclic scaffolds for EGFR as well as HER2 inhibition. We gather some remarkable results for fused-pyrimidine derivatives on various cancerous cell lines (in-vitro) and animal (in-vivo) evaluation to highlight their potency. The heterocyclic (five, six-membered, etc.) moieties which are coupled with pyrimidine moiety are potent against EGFR and HER2 inhibitions. Hence structure-activity relationship (SAR) plays important role in study of heterocyclic moiety along pyrimidine and effects of substituents, groups for increase or decrease in the cancerous activity and toxicity. By thoughtful of fused pyrimidines SAR study, it facilitates in receiving excellent overview of the compounds by concerning of efficacy and potential summary for future EGFR inhibitors. Furthermore, we studied the in-silico interactions of synthesized compounds to evaluate binding affinity towards the key amino acids.. Communicated by Ramaswamy H. Sarma

30 June 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RPROHIT PAL
ROHIT PAL
GTGhanshyam Teli
Ghanshyam Teli
JAJawaid Akhtar
Jawaid Akhtar
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada